Cancer Comorbidities: Clinical Impacts, Mechanistic Insights, and Management Strategies

Abstract

Cancer patients often have comorbidities that complicate treatment and worsen outcomes. Despite ongoing discussions, the interactions between comorbidities and cancer remain insufficiently understood. In addition, a widely accepted consensus on the document, assessment, and management of these comorbidities has not yet been established. This review aims to systematically synthesize current knowledge and propose a comprehensive framework for addressing these gaps. It summarizes the epidemiology and analyzes the clinical impacts of comorbidities on cancer patients, emphasizing the critical role of effective management of cancer comorbidities. It further examines key management challenges, including gaps in mechanisms and clinical evidence, the lack of precise assessment tools, limited management frameworks, and underdeveloped multidisciplinary collaborations. To address the complex interactions between cancer and comorbidities, this review proposes the establishment of Oncology-Comorbidity as a novel discipline and Oncology-Comorbidity Interaction Pathology as a theoretical framework. The assistance of artificial intelligence and real-world data, together with effective multidisciplinary collaborations, is emphasized as an essential management strategy. Comprehensive, patient-centered Life-Course Cohort Studies are identified as indispensable tools. Ultimately, this review aims to advance the understanding of cancer-comorbidity interactions, provide a roadmap for optimizing comorbidities management, and offer an effective pathway to improve prognosis and quality of life for cancer patients.

Keywords

comorbidities mechanisms / Life-Course Cohort Studies / multidisciplinary collaborations / Oncology-Comorbidity / Oncology-Comorbidity Interaction Pathology

References

[1] J. M. Kocarnik, K. Compton, F. E. Dean, et al., “Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” JAMA Oncology8, no. 3 (2022): 420–444.

[2] F. Bray, M. Laversanne, E. Weiderpass, and I. Soerjomataram, “The Ever-Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide,” Cancer127, no. 16 (2021): 3029–3030.

[3] C. Fitzmaurice, D. Abate, N. Abbasi, et al., “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study,” JAMA Oncology5, no. 12 (2019): 1749–1768.

[4] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians74, no. 3 (2024): 229–263.

[5] J. Crawford, D. Herndon, K. Gmitter, and J. Weiss, “The Impact of Myelosuppression on Quality of Life of Patients Treated With Chemotherapy,” Future Oncology20, no. 21 (2024): 1515–1530.

[6] M. Aldarouish, Y. Chen, S. Zheng, A. Dai, and C. Wang, “The Impact of Chemotherapy on the Immunophenotype of Peripheral Blood Lymphocytes and Survival in Patients With Non-Small Cell Lung Cancer,” Journal of Clinical Oncology36, no. 15 (2018): e24125.

[7] Y. Beguin, W. Lybaert, and A. Bosly, “A Prospective Observational Study Exploring the Impact of Iron Status on Response to Darbepoetin Alfa in Patients With Chemotherapy Induced Anemia,” Blood114, no. 22 (2009): 2007.

[8] A. N. Hanania, W. Mainwaring, Y. T. Ghebre, N. A. Hanania, and M. Ludwig, “Radiation-Induced Lung Injury,” Chest156, no. 1 (2019): 150–162.

[9] S. Chen, Z. Cao, K. Prettner, et al., “Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050,” JAMA Oncology9, no. 4 (2023): 465–472.

[10] F. Guida, R. Kidman, J. Ferlay, et al., “Global and Regional Estimates of Orphans Attributed to Maternal Cancer Mortality in 2020,” Nature Medicine28, no. 12 (2022): 2563–2572.

[11] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians68, no. 6 (2018): 394–424.

[12] F. Iacobellis, G. Dell'Aversano Orabona, A. Brillantino, et al., “Common, Less Common, and Unexpected Complications After Bariatric Surgery: A Pictorial Essay,” Diagnostics12, no. 11 (2022): 2637.

[13] S. J. Melby, “The Most Common Complication After Cardiac Surgery Is Associated With Doubled Mortality and Stroke Rates Yet We Know Little About It,” Annals of Thoracic Surgery112, no. 6 (2021): 2093.

[14] C. Thieme, “Retinal Detachment Is a Common Complication After Childhood Cataract Surgery,” Klin Monatsbl Augenh235, no. 4 (2018): 361–362.

[15] J. Naidoo, X. Wang, K. M. Woo, et al., “Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy,” Journal of Clinical Oncology35, no. 7 (2017): 709–717.

[16] Y. Peng, D. Li, J. Wampfler, et al., “Targeted Therapy-Associated Cardiotoxicity in Patients With Stage-IV Lung Cancer With or Without Cardiac Comorbidities,” Oncology Reports53, no. 2 (2024): 25.

[17] K. D. Miller, R. L. Siegel, C. C. Lin, et al., “Cancer Treatment and Survivorship Statistics, 2016,” CA: A Cancer Journal for Clinicians66, no. 4 (2016): 271–289.

[18] G. R. Williams, A. Mackenzie, A. Magnuson, et al., “Comorbidity in Older Adults With Cancer,” Journal of Geriatric Oncology7, no. 4 (2016): 249–257.

[19] G. Dong, J. Feng, F. Sun, J. Chen, and X. M. Zhao, “A Global Overview of Genetically Interpretable Multimorbidities Among Common Diseases in the UK Biobank,” Genome Medicine13, no. 1 (2021): 110.

[20] C. Renzi, A. Kaushal, J. Emery, et al., “Comorbid Chronic Diseases and Cancer Diagnosis: Disease-Specific Effects and Underlying Mechanisms,” Nature Reviews Clinical Oncology16, no. 12 (2019): 746–761.

[21] K. S. Ogle, G. M. Swanson, N. Woods, and F. Azzouz, “Cancer and Comorbidity: Redefining Chronic Diseases,” Cancer88, no. 3 (2000): 653–663.

[22] D. Sarfati, B. Koczwara, and C. Jackson, “The Impact of Comorbidity on Cancer and Its Treatment,” CA: A Cancer Journal for Clinicians66, no. 4 (2016): 337–350.

[23] C. E. J. Vrinzen, L. Delfgou, N. Stadhouders, et al., “A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer,” Cancer Research83, no. 7 (2023): 1147–1157.

[24] D. Sarfati, J. Gurney, B. T. Lim, et al., “Identifying Important Comorbidity Among Cancer Populations Using Administrative Data: Prevalence and Impact on Survival,” Asia-Pacific Journal of Clinical Oncology12, no. 1 (2016): e47–e56.

[25] S. Han, S. Li, Y. Yang, et al., “Mapping Multimorbidity Progression Among 190 Diseases,” Communications Medicine4, no. 1 (2024): 139.

[26] A. Y. Naser, A. N. Hameed, N. Mustafa, et al., “Depression and Anxiety in Patients With Cancer: A Cross-Sectional Study,” Frontiers in Psychology12 (2021): 585534.

[27] K. S. Grotmol, H. C. Lie, J. H. Loge, et al., “Patients With Advanced Cancer and Depression Report a Significantly Higher Symptom Burden Than Non-Depressed Patients,” Palliative and Supportive Care17, no. 2 (2019): 143–149.

[28] N. S. Litofsky, E. Farace, F. Anderson Jr., C. A. Meyers, W. Huang, and E. R. Laws, “Depression in Patients With High-Grade Glioma: Results of the Glioma Outcomes Project,” Neurosurgery54, no. 2 (2004): 358–367.

[29] J. S. Hong and J. Tian, “Prevalence of Anxiety and Depression and Their Risk Factors in Chinese Cancer Patients,” Supportive Care in Cancer22, no. 2 (2014): 453–459.

[30] Y. H. Wang, J. Q. Li, J. F. Shi, et al., “Depression and Anxiety in Relation to Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis of Cohort Studies,” Molecular Psychiatry25, no. 7 (2020): 1487–1499.

[31] J. W. Huang, C. A. Cao, W. H. Zheng, et al., “The Mechanism of Cancer-Depression Comorbidity,” Neuroscience556 (2024): 25–30.

[32] D. Endeshaw, T. A. Walle, and S. Yohannes, “Depression, Anxiety and Their Associated Factors Among Patients With Cancer Receiving Treatment at Oncology Units in Amhara Region, Ethiopia: A Cross-Sectional Study,” BMJ Open12, no. 11 (2022): e063965.

[33] S. de Matos Barbosa, Y. de Lima Medeiros, D. A. A. Marliere, L. L. F. R. Rodrigues, A. S. Guimarães, and J. B. S. Garcia, “Prevalence and Incidence of Chronic Neuropathic Pain and Its Association With Anxiety, Depression, and Sleep Disturbances in Brazilian Head and Neck Cancer Patients,” Supportive Care in Cancer33, no. 11 (2025): 967.

[34] A. Javan Biparva, S. Raoofi, S. Rafiei, et al., “Global Depression in Breast Cancer Patients: Systematic Review and Meta-Analysis,” PLoS One18, no. 7 (2023): e0287372.

[35] A. F. Barnes, T. P. Yeo, B. Leiby, A. Kay, and J. M. Winter, “Pancreatic Cancer-Associated Depression: A Case Report and Review of the Literature,” Pancreas47, no. 9 (2018): 1065–1077.

[36] M. Szabados, E. Kolumbán, G. Agócs, et al., “Association of Tumor Location With Anxiety and Depression in Childhood Brain Cancer Survivors: A Systematic Review and Meta-Analysis,” Child and Adolescent Psychiatry and Mental Health17, no. 1 (2023): 124.

[37] E. L. Zeilinger, C. Oppenauer, M. Knefel, et al., “Prevalence of Anxiety and Depression in People With Different Types of Cancer or Haematologic Malignancies: A Cross-Sectional Study,” Epidemiology and Psychiatric Sciences31 (2022): e74.

[38] R. B. Parikh, J. J. Gallo, Y. N. Wong, et al., “Long-Term Depression Incidence and Associated Mortality Among African American and White Prostate Cancer Survivors,” Cancer127, no. 18 (2021): 3476–3485.

[39] P. Esser, A. Mehnert-Theuerkauf, M. Friedrich, et al., “Risk and Associated Factors of Depression and Anxiety in Men With Prostate Cancer: Results From a German Multicenter Study,” Psycho-Oncology29, no. 10 (2020): 1604–1612.

[40] A. Hessami, E. Ghadirzadeh, S. Ashrafi, et al., “Depression, Anxiety, and Stress in Breast Cancer Patients: Prevalence, Associated Risk Factors, and Clinical Correlates,” Scientific Reports15, no. 1 (2025): 31084.

[41] M. Jung, M. Li, E. Choo, et al., “Incidence of Depression and Anxiety in Kidney Cancer Survivors: A Nationwide Population-Based Cohort Study,” Cancer Epidemiology, Biomarkers & Prevention34, no. 6 (2025): 1027–1035.

[42] K. Kawaguchi, M. Maeda, F. Murata, M. Endo, Y. Nakashima, and H. Fukuda, “Incidence and Temporal Trends of Depression and Anxiety Following Cancer Diagnosis in Japan: Insights From the LIFE Study,” International Journal of Cancer158, no. 3 (2026): 621–632.

[43] X. Gao, M. Guan, B. Bo, W. Zhao, L. Huang, and Y. He, “Prevalence and Associated Factors of Anxiety and Depression in Lung Cancer Patients,” Clinical and Experimental Pharmacology and Physiology52, no. 10 (2025): e70065.

[44] M. A. Richards, S. Hiom, and W. Hamilton, “Diagnosing Cancer Earlier: What Progress Is Being Made?,” British Journal of Cancer128, no. 3 (2023): 441–442.

[45] M. Sogaard, R. W. Thomsen, K. S. Bossen, H. Henrik Toft Sørensen, and M. Nørgaard, “The Impact of Comorbidity on Cancer Survival: A Review,” Clinical Epidemiology5, no. 1 (2013): 3–29.

[46] J. Gurney, D. Sarfati, and J. Stanley, “The Impact of Patient Comorbidity on Cancer Stage at Diagnosis,” British Journal of Cancer113, no. 9 (2015): 1375–1380.

[47] G. Panigrahi and S. Ambs, “How Comorbidities Shape Cancer Biology and Survival,” Trends in Cancer7, no. 6 (2021): 488–495.

[48] C. Renzi and G. Lyratzopoulos, “Comorbidity and the Diagnosis of Symptomatic-but-as-yet-Undiagnosed Cancer,” British Journal of General Practice70, no. 698 (2020): e598–e599.

[49] S. E. Kim, A. E. Bachorik, K. A. Bertrand, and C. M. Gunn, “Differences in Breast Cancer Screening Practices by Diabetes Status and Race/Ethnicity in the United States,” Journal of Women's Health31, no. 6 (2022): 848–855.

[50] C. P. Gross, M. S. Andersen, H. M. Krumholz, G. J. McAvay, D. Proctor, and M. E. Tinetti, “Relation Between Medicare Screening Reimbursement and Stage at Diagnosis for Older Patients With Colon Cancer,” Journal of the American Medical Association296, no. 23 (2006): 2815–2822.

[51] B. C. Reid, J. L. Warren, and G. Rozier, “Comorbidity and Early Diagnosis of Head and Neck Cancer in a Medicare Population,” American Journal of Preventive Medicine27, no. 5 (2004): 373–378.

[52] S. Taneja, S. Mandayam, Z. Z. Kayani, Y. F. Kuo, and V. B. Shahinian, “Comparison of Stage at Diagnosis of Cancer in Patients Who Are on Dialysis Versus the General Population,” Clinical Journal of the American Society of Nephrology2, no. 5 (2007): 1008–1013.

[53] J. Ruszkowski, K. Majkutewicz, Z. Heleniak, J. M. Witkowski, and A. Dębska-Ślizień, “Prevalence and Severity of Lower Gastrointestinal Symptoms Amongst Non-Dialysis Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis,” Journal of Clinical Medicine11, no. 21 (2022): 6363.

[54] J. Li, Z. P. Li, W. J. Ruan, and W. Wang, “Colorectal Cancer Screening: The Value of Early Detection and Modern Challenges,” World Journal of Gastroenterology30, no. 20 (2024): 2726–2730.

[55] S. J. T. Guilcher, A. Lofters, R. H. Glazier, S. B. Jaglal, J. Voth, and A. M. Bayoumi, “Level of Disability, Multi-Morbidity and Breast Cancer Screening: Does Severity Matter?,” Preventive Medicine67 (2014): 193–198.

[56] D. Bhatia, I. C. Lega, W. Wu, and L. L. Lipscombe, “Breast, Cervical and Colorectal Cancer Screening in Adults With Diabetes: A Systematic Review and Meta-Analysis,” Diabetologia63, no. 1 (2020): 34–48.

[57] A. A. Onitilo, J. M. Engel, I. Glurich, R. V. Stankowski, G. M. Williams, and S. A. Doi, “Diabetes and Cancer I: Risk, Survival, and Implications for Screening,” Cancer Causes & Control23, no. 6 (2012): 967–981.

[58] A. A. Siddiqui, S. J. Spechler, S. Huerta, S. Dredar, B. B. Little, and B. Cryer, “Elevated HbA1c Is an Independent Predictor of Aggressive Clinical Behavior in Patients With Colorectal Cancer: A Case-Control Study,” Digestive Diseases and Sciences53, no. 9 (2008): 2486–2494.

[59] D. Boakye, B. Rillmann, V. Walter, L. Jansen, M. Hoffmeister, and H. Brenner, “Impact of Comorbidity and Frailty on Prognosis in Colorectal Cancer Patients: A Systematic Review and Meta-Analysis,” Cancer Treatment Reviews64 (2018): 30–39.

[60] M. Bohdan, A. Kowalczys, A. Mickiewicz, M. Gruchała, and E. Lewicka, “Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives,” Journal of Clinical Medicine10, no. 8 (2021): 1647.

[61] S. Boussios, G. Pentheroudakis, K. Katsanos, and N. Pavlidis, “Systemic Treatment-Induced Gastrointestinal Toxicity: Incidence, Clinical Presentation and Management,” Annals of Gastroenterology25, no. 2 (2012): 106–118.

[62] V. E. P. P. Lemmens, M. L. G. Janssen-Heijnen, S. Houterman, et al., “Which Comorbid Conditions Predict Complications After Surgery for Colorectal Cancer?,” World Journal of Surgery31, no. 1 (2007): 192–199.

[63] A. W. Dreisbach and J. J. Lertora, “The Effect of Chronic Renal Failure on Drug Metabolism and Transport,” Expert Opinion on Drug Metabolism & Toxicology4, no. 8 (2008): 1065–1074.

[64] W. L. Chiou, “A New Model-Independent Physiological Approach to Study Hepatic Drug Clearance and Its Applications,” International Journal of Clinical Pharmacology, Therapy, and Toxicology22, no. 11 (1984): 577–590.

[65] T. Fainsod-Levi, M. Gershkovitz, S. Völs, et al., “Hyperglycemia Impairs Neutrophil Mobilization Leading to Enhanced Metastatic Seeding,” Cell Reports21, no. 9 (2017): 2384–2392.

[66] C. Yim, K. Mansell, N. Hussein, and T. Arnason, “Current Cancer Therapies and Their Influence on Glucose Control,” World Journal of Diabetes12, no. 7 (2021): 1010–1025.

[67] A. J. Frank, I. Dagogo-Jack, I. A. Dobre, et al., “Management of Lung Cancer in the Patient With Interstitial Lung Disease,” Oncologist28, no. 1 (2023): 12–22.

[68] P. Tarantino, S. Modi, S. M. Tolaney, et al., “Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates A Review,” Jama Oncology7, no. 12 (2021): 1873–1881.

[69] L. Cagini, S. Balloni, V. Ludovini, et al., “Variations in Gene Expression of Lung Macromolecules After Induction Chemotherapy for Lung Cancer,” European Journal of Cardio-Thoracic Surgery52, no. 6 (2017): 1077–1082.

[70] X. Peng, “The Cardiotoxicology of Anthracycline Chemotherapeutics: Translating Molecular Mechanism Into Preventative Medicine,” Molecular Interventions5, no. 3 (2005): 163–171.

[71] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity,” Pharmacological Reviews56, no. 2 (2004): 185–229.

[72] S. M. Swain, F. S. Whaley, and M. S. Ewer, “Congestive Heart Failure in Patients Treated With Doxorubicin - A Retrospective Analysis of Three Trials,” Cancer97, no. 11 (2003): 2869–2879.

[73] A. Tzouvelekis, G. Gomatou, E. Bouros, R. Trigidou, V. Tzilas, and D. Bouros, “Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer,” Chest156, no. 2 (2019): 383–391.

[74] D. Zhu, R. Ding, Y. Ma, Z. Chen, X. Shi, and P. He, “Comorbidity in Lung Cancer Patients and Its Association With Hospital Readmission and Fatality in China,” BMC Cancer21, no. 1 (2021): 557.

[75] H. Y. Lee, J. Lee, C. H. Lee, K. Han, and S. M. Choi, “Risk of Cancer Incidence in Patients With Idiopathic Pulmonary Fibrosis: A Nationwide Cohort Study,” Respirology26, no. 2 (2021): 180–187.

[76] K. Maretty-Nielsen, N. Aggerholm-Pedersen, A. Safwat, S. Baerentzen, A. B. Pedersen, and J. Keller, “Prevalence and Prognostic Impact of Comorbidity in Soft Tissue Sarcoma: A Population-Based Cohort Study,” Acta Oncologica53, no. 9 (2014): 1188–1196.

[77] M. S. Frank and U. Bodtger, “An Individualized Approach to Comorbidities in Lung Cancer,” Journal of Thoracic Oncology18, no. 3 (2023): 254–256.

[78] W. Wang, S. Dou, W. Dong, et al., “Impact of COPD on Prognosis of Lung Cancer: From a Perspective on Disease Heterogeneity,” International Journal of Chronic Obstructive Pulmonary Disease13 (2018): 3767–3776.

[79] J. F. Piccirillo, “Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry,” Journal of the American Medical Association291, no. 20 (2004): 2441–2447.

[80] B. Knettel, K. Corrigan, E. Cherenack, et al., “HIV, Cancer, and Coping: The Cumulative Burden of a Cancer Diagnosis Among People Living With HIV,” Journal of Psychosocial Oncology39, no. 6 (2021): 734–748.

[81] A. E. Coghill, G. Suneja, A. F. Rositch, M. S. Shiels, and E. A. Engels, “HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States,” JAMA Oncology5, no. 9 (2019): e191742.

[82] Y. H. Wang and X. D. Shen, “Human Immunodeficiency Virus Infection and Mortality Risk Among Lung Cancer Patients a Systematic Review and Meta-Analysis,” Medicine97, no. 15 (2018): e0361.

[83] D. W. Frost, D. J. Cook, D. K. Heyland, and R. A. Fowler, “Patient and Healthcare Professional Factors Influencing End-of-Life Decision-Making During Critical Illness: A Systematic Review,” Critical Care Medicine39, no. 5 (2011): 1174–1189.

[84] S. McPhail, “Multimorbidity in Chronic Disease: Impact on Health Care Resources and Costs,” Risk Management and Healthcare Policy9 (2016): 143–156.

[85] L. T. Pinsoneault, E. R. Connors, E. A. Jacobs, and J. Broeckling, “Go Slow to Go Fast: Successful Engagement Strategies for Patient-Centered, Multi-Site Research, Involving Academic and Community-Based Organizations,” Journal of General Internal Medicine34, no. 1 (2019): 125–131.

[86] S. M. Smith, E. Wallace, T. O'Dowd, and M. Fortin, “Interventions for Improving Outcomes in Patients With Multimorbidity in Primary Care and Community Settings,” Cochrane Database of Systematic Reviews3, no. 3 (2016): CD006560.

[87] A. Woolley and O. Kostopoulou, “Clinical Intuition in Family Medicine: More Than First Impressions,” Annals of Family Medicine11, no. 1 (2013): 60–66.

[88] E. Mendenhall, B. A. Kohrt, S. A. Norris, D. Ndetei, and D. Prabhakaran, “Non-Communicable Disease Syndemics: Poverty, Depression, and Diabetes Among Low-Income Populations,” Lancet389, no. 10072 (2017): 951–963.

[89] C. Hajat and E. Stein, “The Global Burden of Multiple Chronic Conditions: A Narrative Review,” Preventive Medicine Reports12 (2018): 284–293.

[90] G. Sum, T. Hone, R. Atun, et al., “Multimorbidity and Out-of-Pocket Expenditure on Medicines: A Systematic Review,” BMJ Global Health3, no. 1 (2018): e000505.

[91] G. Hajishengallis and T. Chavakis, “Local and Systemic Mechanisms Linking Periodontal Disease and Inflammatory Comorbidities,” Nature Reviews Immunology21, no. 7 (2021): 426–440.

[92] A. Forder, R. Zhuang, V. G. P. Souza, et al., “Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer,” International Journal of Molecular Sciences24, no. 3 (2023): 2859.

[93] J. Zeng, D. Shi, D. He, W. Dong, Z. Yang, and Y. Chen, “Comorbidity of Hypertension and Lung Cancer: Interplay of Genetics and Environment,” Discover Oncology16, no. 1 (2025): 1548.

[94] A. M. Houghton, “Mechanistic Links Between COPD and Lung Cancer,” Nature Reviews Cancer13, no. 4 (2013): 233–245.

[95] A. S. Yende and D. Sharma, “Obesity, Dysbiosis and Inflammation: Interactions That Modulate the Efficacy of Immunotherapy,” Frontiers in Immunology15 (2024): 1444589.

[96] A. W. Armstrong and C. Read, “Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review,” Journal of the American Medical Association323, no. 19 (2020): 1945–1960.

[97] I. Sulaiman, B. G. Wu, M. Chung, et al., “Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine208, no. 10 (2023): 1101–1114.

[98] E. Dima, O. Koltsida, P. Katsaounou, et al., “Implication of Interleukin (IL)-18 in the Pathogenesis of Chronic Obstructive Pulmonary Disease (COPD),” Cytokine74, no. 2 (2015): 313–317.

[99] D. Wang, S. Li, Z. Yang, et al., “Single-Cell Transcriptome Analysis Deciphers the CD74-Mediated Immune Evasion and Tumour Growth in Lung Squamous Cell Carcinoma With Chronic Obstructive Pulmonary Disease,” Clinical and Translational Medicine14, no. 8 (2024): e1786.

[100] M. Karin and H. Clevers, “Reparative Inflammation Takes Charge of Tissue Regeneration,” Nature529, no. 7586 (2016): 307–315.

[101] R. Lattanzi, C. Severini, and R. Miele, “Prokineticin 2 in Cancer-Related Inflammation,” Cancer Letters546 (2022): 215838.

[102] L. Paschold, C. Schultheiss, P. Schmidt-Barbo, et al., “Inflammation and Limited Adaptive Immunity Predict Worse Outcomes on Immunotherapy in Head and Neck Cancer,” npj Precision Oncology9, no. 1 (2025): 272.

[103] R. Noy and J. W. Pollard, “Tumor-Associated Macrophages: From Mechanisms to Therapy,” Immunity41, no. 1 (2014): 49–61.

[104] S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, Inflammation, and Cancer,” Cell140, no. 6 (2010): 883–899.

[105] M. Karin and F. R. Greten, “NF-κB: Linking Inflammation and Immunity to Cancer Development and Progression,” Nature Reviews Immunology5, no. 10 (2005): 749–759.

[106] C. Porta, M. Rimoldi, G. Raes, et al., “Tolerance and M2 (Alternative) Macrophage Polarization Are Related Processes Orchestrated by p50 Nuclear Factor κB,” Proceedings of the National Academy of Sciences106, no. 35 (2009): 14978–14983.

[107] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-Related Inflammation,” Nature454, no. 7203 (2008): 436–444.

[108] H. Mao, X. Zhao, and S. Sun, “NF-κB in Inflammation and Cancer,” Cellular & Molecular Immunology22, no. 8 (2025): 811–839.

[109] G. C. Prendergast, C. Smith, S. Thomas, et al., “Indoleamine 2,3-dioxygenase Pathways of Pathogenic Inflammation and Immune Escape in Cancer,” Cancer Immunology, Immunotherapy63, no. 7 (2014): 721–735.

[110] C. A. Opitz, U. M. Litzenburger, F. Sahm, et al., “An Endogenous Tumour-Promoting Ligand of the Human Aryl Hydrocarbon Receptor,” Nature478, no. 7368 (2011): 197–203.

[111] D. H. Munn and A. L. Mellor, “IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance,” Trends in Immunology37, no. 3 (2016): 193–207.

[112] J. Thaiparambil, L. Dong, D. Jasso, J. A. Huang, and R. A. El-Zein, “Mitotic Spindle Apparatus Abnormalities in Chronic Obstructive Pulmonary Disease Cells: A Potential Pathway to Lung Cancer,” Cancer Prevention Research13, no. 11 (2020): 923–934.

[113] L. Wang, H. Zhao, L. Zhang, H. Luo, Q. Chen, and X. Zuo, “HSP90AA1, ADRB2, TBL1XR1 and HSPB1 Are Chronic Obstructive Pulmonary Disease-Related Genes That Facilitate Squamous Cell Lung Cancer Progression,” Oncology Letters19, no. 3 (2020): 2115–2122.

[114] O. Sweef, R. Mahfouz, T. Taşcıoğlu, et al., “Decoding LncRNA in COPD: Unveiling Prognostic and Diagnostic Power and Their Driving Role in Lung Cancer Progression,” International Journal of Molecular Sciences25, no. 16 (2024): 9001.

[115] B. Arcidiacono, S. Iiritano, A. Nocera, et al., “Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms,” Experimental Diabetes Research2012 (2012): 789174.

[116] W. Duan, X. Shen, J. Lei, et al., “Hyperglycemia, a Neglected Factor During Cancer Progression,” BioMed Research International2014 (2014): 461917.

[117] C. X. Xu, “Diabetes and Cancer: Associations, Mechanisms, and Implications for Medical Practice,” World Journal of Diabetes5, no. 3 (2014): 372–380.

[118] A. Singh, S. Shadangi, P. K. Gupta, and S. Rana, “Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies,” Comprehensive Physiology15, no. 1 (2025): e70003.

[119] W. Wang, L. A. Hapach, L. Griggs, et al., “Diabetic Hyperglycemia Promotes Primary Tumor Progression Through Glycation-Induced Tumor Extracellular Matrix Stiffening,” Science Advances8, no. 46 (2022): 1673.

[120] W. Fan, K. Adebowale, L. Váncza, et al., “Matrix Viscoelasticity Promotes Liver Cancer Progression in the Pre-Cirrhotic Liver,” Nature626, no. 7999 (2024): 635–642.

[121] W. Wang, L. A. Hapach, P. V. Taufalele, M. E. Bates, Y. Wu, and C. A. Reinhart-King, “Diabetic Hyperglycemia-Induced Glycation Regulates Tumor Vasculature Integrity via NF-kappa B-Mediated GM-CSF Secretion by Tumor Cells,” Cell Biomater1, no. 9 (2025): 100186.

[122] J. Han, L. Dong, M. Wu, and F. Ma, “Dynamic Polarization of Tumor-Associated Macrophages and Their Interaction With Intratumoral T Cells in an Inflamed Tumor Microenvironment: From Mechanistic Insights to Therapeutic Opportunities,” Frontiers in Immunology14 (2023): 1160340.

[123] E. Mitsui, S. Kikuchi, T. Okura, et al., “Novel Treatment Strategy Targeting Interleukin-6 Induced by Cancer Associated Fibroblasts for Peritoneal Metastasis of Gastric Cancer,” Scientific Reports15, no. 1 (2025): 3267.

[124] Y. W. Ling, J. L. Duan, Z. J. Jiang, et al., “Diabetes Reshapes Pancreatic Cancer-Associated Endothelial Niche by Accelerating Senescence,” Nature Communications16, no. 1 (2025): 8654.

[125] Z. Ansari, A. Chaurasia, Neha, N. Sharma, R. K. Bachheti, and P. C. Gupta, “Exploring Inflammatory and Fibrotic Mechanisms Driving Diabetic Nephropathy Progression,” Cytokine & Growth Factor Reviews84 (2025): 120–134.

[126] P. Y. Thimmappa, S. Vasishta, K. Ganesh, A. S. Nair, and M. B. Joshi, “Neutrophil (dys)function due to Altered Immuno-Metabolic Axis in Type 2 Diabetes: Implications in Combating Infections,” Human Cell36, no. 4 (2023): 1265–1282.

[127] D. Qiu, L. Zhang, J. Zhan, et al., “Hyperglycemia Decreases Epithelial Cell Proliferation and Attenuates Neutrophil Activity by Reducing ICAM-1 and LFA-1 Expression Levels,” Frontiers in Genetics11 (2020): 616988.

[128] R. Ruze, J. Song, X. Yin, et al., “Mechanisms of Obesity- and Diabetes Mellitus-Related Pancreatic Carcinogenesis: A Comprehensive and Systematic Review,” Signal Transduction and Targeted Therapy8, no. 1 (2023): 139.

[129] G. Musso, R. Gambino, and M. Cassader, “Obesity, Diabetes, and Gut Microbiota,” Diabetes Care33, no. 10 (2010): 2277–2284.

[130] K. A. Rumyantsev, V. V. Polyakova, I. V. Sorokina, et al., “The Gut Microbiota Impacts Gastrointestinal Cancers Through Obesity, Diabetes, and Chronic Inflammation,” Life14, no. 10 (2024): 1219.

[131] G. Shen, J. Liu, Y. Wang, Z. Deng, and F. Deng, “Ferroptosis in Cancer and Inflammatory Diseases: Mechanisms and Therapeutic Implications,” MedComm (2020)6, no. 9 (2025): e70349.

[132] X. Liang, J. Weng, Z. You, et al., “Oxidative Stress in Cancer: From Tumor and Microenvironment Remodeling to Therapeutic Frontiers,” Molecular Cancer24, no. 1 (2025): 219.

[133] A. Vasconcelos-dos-Santos, H. F. B. R. Loponte, N. R. Mantuano, et al., “Hyperglycemia Exacerbates Colon Cancer Malignancy Through Hexosamine Biosynthetic Pathway,” Oncogenesis6 (2017): e306.

[134] S. Pan, K. Yin, Z. Tang, et al., “Stimulation of Hypothalamic Oxytocin Neurons Suppresses Colorectal Cancer Progression in Mice,” eLife10 (2021): e67535.

[135] Y. Xu, J. Yan, Y. Tao, et al., “Pituitary Hormone α-MSH Promotes Tumor-Induced Myelopoiesis and Immunosuppression,” Science377, no. 6610 (2022): 1085–1091.

[136] H. Yang, L. Xia, J. Chen, et al., “Stress-Glucocorticoid-TSC22D3 Axis Compromises Therapy-Induced Antitumor Immunity,” Nature Medicine25, no. 9 (2019): 1428–1441.

[137] Z. Ye, K. Ganesan, M. Wu, et al., “Crosstalk Between Depression and Breast Cancer via Hepatic Epoxide Metabolism: A Central Comorbidity Mechanism,” Molecules27, no. 21 (2022): 7269.

[138] M. Berk, O. Köhler-Forsberg, M. Turner, et al., “Comorbidity Between Major Depressive Disorder and Physical Diseases: A Comprehensive Review of Epidemiology, Mechanisms and Management,” World Psychiatry: Official Journal of the World Psychiatric Association (WPA)22, no. 3 (2023): 366–387.

[139] B. Bortolato, T. N. Hyphantis, S. Valpione, et al., “Depression in Cancer: The Many Biobehavioral Pathways Driving Tumor Progression,” Cancer Treatment Reviews52 (2017): 58–70.

[140] H. S. Wirtshafter and M. A. Wilson, “Lateral Septum as a Nexus for Mood, Motivation, and Movement,” Neuroscience & Biobehavioral Reviews126 (2021): 544–559.

[141] C. A. Rizzi-Wise and D. V. Wang, “Putting Together Pieces of the Lateral Septum: Multifaceted Functions and Its Neural Pathways,” eNeuro8, no. 6 (2021): 0315–0321.

[142] Y. Li, H. Yu, Z. M. Li, et al., “Colorectal Cancer Cells Hijack a Brain-Gut Polysynaptic Circuit From the Lateral Septum to Enteric Neurons to Sustain Tumor Growth,” Nature Cancer6, no. 11 (2025): 1800–1820.

[143] A. Singh, J. J. Nunes, and B. Ateeq, “Role and Therapeutic Potential of G-Protein Coupled Receptors in Breast Cancer Progression and Metastases,” Eur J Pharmacol, Pt B (2015): 178–183.

[144] M. Voigtlaender, K. Holstein, S. Leuenroth, J. Mudter, C. Bokemeyer, and F. Langer, “Clinical Evidence That Coagulation Activation Drives Cancer Progression—A Report of 2 Cases,” Oncology Research and Treatment38, no. 9 (2015): 449–452.

[145] S. Chaudhari, B. M. D'Souza, J. Y. Morales, et al., “Renal TLR-7/TNF-α Pathway as a Potential Female-Specific Mechanism in the Pathogenesis of Autoimmune-Induced Hypertension,” American Journal of Physiology-Heart and Circulatory Physiology323, no. 6 (2022): H1331–H1342.

[146] M. Kim, C. Lee, and J. Park, “Extracellular Matrix Remodeling Facilitates Obesity-Associated Cancer Progression,” Trends in Cell Biology32, no. 10 (2022): 825–834.

[147] K. Xu, A. Fu, Z. Li, et al., “Elevated Extracellular Matrix Protein 1 in Circulating Extracellular Vesicles Supports Breast Cancer Progression under Obesity Conditions,” Nature Communications15, no. 1 (2024): 1685.

[148] J. Li and R. Xu, “Obesity-Associated ECM Remodeling in Cancer Progression,” Cancers14, no. 22 (2022): 5684.

[149] D. Kong, X. Li, S. Zhao, et al., “Adipose Tissue-Secreted Spz5 Promotes Distal Tumor Progression via Toll-6-Mediated Hh Pathway Activation in Drosophila,” EMBO Journal44, no. 15 (2025): 4301–4330.

[150] J. W. Kim, J. H. Kim, and Y. J. Lee, “The Role of Adipokines in Tumor Progression and Its Association With Obesity,” Biomedicines12, no. 1 (2024): 97.

[151] F. Li, S. Hao, J. Gao, and P. Jiang, “EGCG Alleviates Obesity-Exacerbated Lung Cancer Progression by STAT1/SLC7A11 Pathway and Gut Microbiota,” Journal of Nutritional Biochemistry120 (2023): 109416.

[152] J. Ghimire, M. E. Collins, P. Snarski, et al., “Obesity-Facilitated Colon Cancer Progression Is Mediated by Increased Diacylglycerol O-Acyltransferases 1 and 2 Levels,” Gastroenterology168, no. 2 (2025): 286–299.e6.

[153] T. Taha, E. Hall, and J. S. de Bono, “Mind the Gap: The Disconnect Between Clinical Trials and Real-World Oncology Patients,” European Urology87, no. 5 (2025): 501–503.

[154] T. Scully, A. Ettela, D. LeRoith, and E. J. Gallagher, “Obesity, Type 2 Diabetes, and Cancer Risk,” Frontiers in Oncology10 (2021): 615375.

[155] Z. Zelenko, E. J. Gallagher, A. Tobin-Hess, et al., “Silencing Vimentin Expression Decreases Pulmonary Metastases in a Pre-Diabetic Mouse Model of Mammary Tumor Progression,” Oncogene36, no. 10 (2017): 1394–1403.

[156] A. A. Alshahrani, E. Kontopantelis, C. Morgan, R. Ravindrarajah, G. P. Martin, and M. A. Mamas, “Cardiovascular Diseases in Patients With Cancer: A Comprehensive Review of Epidemiological Trends, Cardiac Complications, and Prognostic Implications,” Chinese Medical Journal138, no. 2 (2025): 143–154.

[157] J. Muhandiramge, J. R. Zalcberg, G. J. van Londen, et al., “Cardiovascular Disease in Adult Cancer Survivors: A Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-Oncology,” Current Oncology Reports24, no. 11 (2022): 1579–1592.

[158] I. G. Scalia, B. Gheyath, B. K. Tamarappoo, et al., “Chemotherapy Related Cardiotoxicity Evaluation-A Contemporary Review With a Focus on Cardiac Imaging,” Journal of Clinical Medicine13, no. 13 (2024): 3714.

[159] Y. Guo, B. Hu, Y. Xie, et al., “Regulation of Drug-Metabolizing Enzymes by Local and Systemic Liver Injuries,” Expert Opinion on Drug Metabolism & Toxicology12, no. 3 (2016): 245–251.

[160] M. Zhao, J. Ma, M. Li, et al., “Cytochrome P450 Enzymes and Drug Metabolism in Humans,” International Journal of Molecular Sciences22, no. 23 (2021): 12808.

[161] R. P. Miller, R. K. Tadagavadi, G. Ramesh, and W. B. Reeves, “Mechanisms of Cisplatin Nephrotoxicity,” Toxins2, no. 11 (2010): 2490–2518.

[162] J. M. T. Colombijn, D. L. Idema, S. van Beem, et al., “Representation of Patients With Chronic Kidney Disease in Clinical Trials of Cardiovascular Disease Medications: A Systematic Review,” JAMA Network Open7, no. 3 (2024): e240427.

[163] J. Sakowska, Ł. Arcimowicz, M. Jankowiak, et al., “Autoimmunity and Cancer-Two Sides of the Same Coin,” Frontiers in immunology13 (2022): 793234.

[164] A. Young, Z. Quandt, and J. A. Bluestone, “The Balancing Act Between Cancer Immunity and Autoimmunity in Response to Immunotherapy,” Cancer Immunology Research6, no. 12 (2018): 1445–1452.

[165] H. R. Smith, “Depression in Cancer Patients: Pathogenesis, Implications and Treatment (Review),” Oncology Letters9, no. 4 (2015): 1509–1514.

[166] C. L. Raison and A. H. Miller, “The Evolutionary Significance of Depression in Pathogen Host Defense (PATHOS-D),” Molecular Psychiatry18, no. 1 (2013): 15–37.

[167] D. Spiegel and J. Giese-Davis, “Depression and Cancer: Mechanisms and Disease Progression,” Biological Psychiatry54, no. 3 (2003): 269–282.

[168] L. Ye, Y. Hou, W. Hu, et al., “Repressed Blautia-Acetate Immunological Axis Underlies Breast Cancer Progression Promoted by Chronic Stress,” Nature Communications14, no. 1 (2023): 6160.

[169] Z. Li, W. Zheng, H. Wang, et al., “Application of Animal Models in Cancer Research: Recent Progress and Future Prospects,” Cancer Management and Research13 (2021): 2455–2475.

[170] K. M. Schachtschneider, R. M. Schwind, J. Newson, et al., “The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform,” Frontiers in Oncology7 (2017): 190.

[171] J. A. Meyerhardt, P. J. Catalano, D. G. Haller, et al., “Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer,” Journal of Clinical Oncology21, no. 3 (2003): 433–440.

[172] C. P. Gross, Z. Guo, G. J. McAvay, H. G. Allore, M. Young, and M. E. Tinetti, “Multimorbidity and Survival in Older Persons With Colorectal Cancer,” Journal of the American Geriatrics Society54, no. 12 (2006): 1898–1904.

[173] E. J. Feuer, M. Lee, A. B. Mariotto, et al., “The Cancer Survival Query System: Making Survival Estimates From the Surveillance, Epidemiology, and End Results Program More Timely and Relevant for Recently Diagnosed Patients,” Cancer118, no. 22 (2012): 5652–5662.

[174] C. J. Newschaffer, T. L. Bush, and L. T. Penberthy, “Comorbidity Measurement in Elderly Female Breast Cancer Patients With Administrative and Medical Records Data,” Journal of Clinical Epidemiology50, no. 6 (1997): 725–733.

[175] C. M. Tammemagi, C. Neslund-Dudas, M. Simoff, and P. Kvale, “Impact of Comorbidity on Lung Cancer Survival,” International Journal of Cancer103, no. 6 (2003): 792–802.

[176] M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, “A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation,” Journal of Chronic Diseases40, no. 5 (1987): 373–383.

[177] D. Sarfati, J. Gurney, J. Stanley, B. T. Lim, and C. McSherry, “Development of a Pharmacy-Based Comorbidity Index for Patients With Cancer,” Medical Care52, no. 7 (2014): 586–593.

[178] J. F. Piccirillo, “Importance of Comorbidity in Head and Neck Cancer,” Laryngoscope110, no. 4 (2000): 593–602.

[179] J. F. Piccirillo, E. L. Spitznagel Jr., N. Vermani, I. Costas, and M. Schnitzler, “Comparison of Comorbidity Indices for Patients With Head and Neck Cancer,” Medical Care42, no. 5 (2004): 482–486.

[180] S. Milne, J. Parmar, and T. K. Ong, “Adult Comorbidity Evaluation-27 as a Predictor of Postoperative Complications, Two-Year Mortality, Duration of Hospital Stay, and Readmission Within 30 Days in Patients With Squamous Cell Carcinoma of the Head and Neck,” British Journal of Oral and Maxillofacial Surgery57, no. 3 (2019): 214–218.

[181] A. R. Monteiro, A. R. Garcia, T. C. Pereira, et al., “ACE-27 as a Prognostic Tool of Severe Acute Toxicities in Patients With Head and Neck Cancer Treated With Chemoradiotherapy: A Real-World, Prospective, Observational Study,” Supportive Care in Cancer29, no. 4 (2021): 1863–1871.

[182] K. Kim, H. Kantarjian, E. J. Jabbour, et al., “The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors,” Blood138 (2021): 2554.

[183] A. Drosdowsky and K. Gough, “The Charlson Comorbidity Index: Problems With Use in Epidemiological Research,” Journal of Clinical Epidemiology148 (2022): 174–177.

[184] C. E. Roffman, J. Buchanan, and G. T. Allison, “Charlson Comorbidities Index,” Journal of Physiotherapy62, no. 3 (2016): 171.

[185] R. Castelli, P. Bucciarelli, F. Porro, F. Depetri, and M. Cugno, “Pulmonary Embolism in Elderly Patients: Prognostic Impact of the Cumulative Illness Rating Scale (CIRS) on Short-Term Mortality,” Thrombosis Research134, no. 2 (2014): 326–330.

[186] D. Di Raimondo, E. Pirera, C. Pintus, et al., “The Role of the Cumulative Illness Rating Scale (CIRS) in Estimating the Impact of Comorbidities on Chronic Obstructive Pulmonary Disease (COPD) Outcomes: A Pilot Study of the MACH (Multidimensional Approach for COPD and High Complexity) Study,” Journal of Personalized Medicine13, no. 12 (2023): 1674.

[187] N. Bashi, F. Fatehi, M. Mosadeghi-Nik, M. S. Askari, and M. Karunanithi, “Digital Health Interventions for Chronic Diseases: A Scoping Review of Evaluation Frameworks,” BMJ Health & Care Informatics27, no. 1 (2020): e100066.

[188] R. C. Brownson, P. Allen, R. R. Jacob, et al., “Controlling Chronic Diseases Through Evidence-Based Decision Making: A Group-Randomized Trial,” Preventing chronic disease14 (2017): 170326.

[189] L. H. Goetz and N. J. Schork, “Personalized Medicine: Motivation, Challenges, and Progress,” Fertility and Sterility109, no. 6 (2018): 952–963.

[190] A. Ribas and J. D. Wolchok, “Cancer Immunotherapy Using Checkpoint Blockade,” Science359, no. 6382 (2018): 1350–1355.

[191] E. J. Topol, “High-Performance Medicine: The Convergence of Human and Artificial Intelligence,” Nature Medicine25, no. 1 (2019): 44–56.

[192] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians71, no. 3 (2021): 209–249.

[193] Y. Hu, Y. Zhou, N. Dai, et al., “Enhancing Panvascular Medicine: Unveiling the Nexus of Pan-Cardio-Oncology and Expanding Therapeutic Frontiers,” Science Bulletin70, no. 6 (2025): 798–800.

[194] C. Zhou, Y. Qin, W. Zhao, et al., “International Expert Consensus on Diagnosis and Treatment of Lung Cancer Complicated by Chronic Obstructive Pulmonary Disease,” Translational Lung Cancer Research12, no. 8 (2023): 1661–1701.

[195] C. Zhou, T. Luan, W. Guan, et al., “Oncology-Respirology: A Discipline in Dire Need,” Trends in Cancer10, no. 9 (2024): 777–780.

[196] A. H. Dur Karasayar, I. Kulac, and N. Kapucuoglu, “Advances in Breast Cancer Care: The Role of Artificial Intelligence and Digital Pathology in Precision Medicine,” European Journal of Breast Health21, no. 2 (2025): 93–100.

[197] S. Vranic and Z. Gatalica, “The Role of Pathology in the Era of Personalized (Precision) Medicine: A Brief Review,” Acta Medica Academica50, no. 1 (2021): 47–57.

[198] K. Bera, K. A. Schalper, D. L. Rimm, V. Velcheti, and A. Madabhushi, “Artificial Intelligence in Digital Pathology —New Tools for Diagnosis and Precision Oncology,” Nature Reviews Clinical Oncology16, no. 11 (2019): 703–715.

[199] N. A. VanderWalde, T. Dockter, D. V. Wakefield, et al., “Disparities in Older Adult Accrual to Cancer Trials: Analysis From the Alliance for Clinical Trials in Oncology,” Journal of Geriatric Oncology13, no. 1 (2022): 20–26.

[200] O. C. Sheehan, B. Leff, C. S. Ritchie, et al., “A Systematic Literature Review of the Assessment of Treatment Burden Experienced by Patients and Their Caregivers,” BMC Geriatrics19, no. 1 (2019): 262.

[201] P. Ravasco, I. Monteiro-Grillo, P. M. Vidal, and M. E. Camilo, “Dietary Counseling Improves Patient Outcomes: A Prospective, Randomized, Controlled Trial in Colorectal Cancer Patients Undergoing Radiotherapy,” Journal of Clinical Oncology23, no. 7 (2005): 1431–1438.

[202] C. L. Rock, C. Doyle, W. Demark-Wahnefried, et al., “Nutrition and Physical Activity Guidelines for Cancer Survivors,” CA: A Cancer Journal for Clinicians62, no. 4 (2012): 242–274.

[203] E. Basch, A. M. Deal, M. G. Kris, et al., “Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial,” Journal of Clinical Oncology34, no. 6 (2016): 557–565.

[204] F. Denis, E. Basch, A. L. Septans, et al., “Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer,” Journal of the American Medical Association321, no. 3 (2019): 306–307.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).